AbbVie Inc vs Dollar General Corp. — how do they compare? AbbVie Inc trades at $284 (market cap $510.84B), while Dollar General Corp. trades at $137.11 (market cap $30.69B). The key difference: AbbVie Inc is far larger — about 16.6× Dollar General Corp.'s market cap, and AbbVie Inc pays the higher dividend (2.39%). Which is the better fit depends on your goals — on Pluang, investors hold AbbVie Inc for 93 Days and Dollar General Corp. for 59 Days on average.
| ABBV | DG | |
|---|---|---|
Market Cap | $510.84B | $30.69B |
Volume | 5,173,329 | 2,729,027 |
Sector | Health | Consumer Staples |
52-Week High | $289.00 | $156.26 |
52-Week Low | $197.38 | $95.94 |
Typical Hold Time | 93 Days | 59 Days |
Enterprise Value | $575.09B | $44.87B |
Dividend Yield | 2.39% | 1.7% |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $284.72, down 1.48% on the day, with strong technical momentum showing bullish moving averages and key support at $282. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, while revenue growth continues with 2025 revenue reaching $61.16B. Recent positive clinical data for ovarian cancer treatment ELAHERE and institutional buying activity support investor confidence.
AbbVie presents a favorable investment case with 72.7% analyst buy ratings and a $294 consensus price target offering 3.3% upside. Key opportunities include robust immunology portfolio growth with Skyrizi and Rinvoq offsetting Humira declines, while risks involve patent cliffs in the 2030s and ongoing legal challenges regarding drug pricing programs.
Dollar General (DG) trades at $132.12, down 1.56% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.48 surpassing the $2.01 estimate. Revenue growth is steady, reaching $40.61B in 2025, though net income margin has compressed to 2.77%. Recent developments include expansion of same-day delivery via Instacart and positive impacts from tariff refunds on margins.
The outlook is supported by a 55.77% analyst buy rating and a $137.27 consensus price target, implying modest upside. Key risks include competitive pressures in discount retail and sensitivity to consumer spending trends. The stock presents a value opportunity with a P/E of 17.16 and P/S of 0.67, but investors should monitor margin recovery and execution of growth initiatives like the DG Media Network.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →